Neuralstem, Inc. (NASDAQ:CUR) was the recipient of a large decrease in short interest in the month of September. As of September 29th, there was short interest totalling 479,425 shares, a decrease of 46.1% from the September 15th total of 888,788 shares. Approximately 5.1% of the shares of the company are sold short. Based on an average daily volume of 1,367,130 shares, the short-interest ratio is presently 0.4 days.

Several institutional investors and hedge funds have recently modified their holdings of CUR. National Asset Management Inc. increased its holdings in shares of Neuralstem by 9.2% in the 2nd quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock valued at $134,000 after purchasing an additional 1,937 shares during the period. Blair William & Co. IL increased its holdings in shares of Neuralstem by 171.0% in the 2nd quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock valued at $506,000 after purchasing an additional 55,115 shares during the period. Alethea Capital Management LLC increased its holdings in shares of Neuralstem by 100.0% in the 2nd quarter. Alethea Capital Management LLC now owns 328,788 shares of the company’s stock valued at $1,904,000 after purchasing an additional 164,394 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Neuralstem by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock valued at $2,000,000 after purchasing an additional 3,853 shares during the period. Institutional investors own 7.33% of the company’s stock.

Separately, ValuEngine cut shares of Neuralstem from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th.

Neuralstem (NASDAQ CUR) opened at 1.35 on Thursday. Neuralstem has a 12-month low of $0.22 and a 12-month high of $6.60. The firm’s 50-day moving average is $1.27 and its 200 day moving average is $3.39. The stock’s market capitalization is $16.36 million.

Neuralstem (NASDAQ:CUR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%. Equities research analysts anticipate that Neuralstem will post ($2.26) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Neuralstem, Inc. (CUR) Short Interest Down 46.1% in September” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/neuralstem-inc-cur-short-interest-down-46-1-in-september/1639864.html.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.